ĀÜĄņĀŅĀ×

David M. Mott has served as a director since December 2009 and is a private investor through Mott Family Capital. From September 2008 to February 2020, Mr. Mott was a general partner at New Enterprise Associates (ā€œNEAā€) and led the healthcare investing practice. NEA is among the largest venture capital firms in the world and invests across all stages in healthcare and technology. At NEA, Mr. Mottā€™s personal investing practice was primarily focused on biopharmaceuticals. Prior to joining NEA, Mr. Mott was president and chief executive officer of biotechnology company MedImmune. He joined MedImmune in 1992 and served in various roles, including president and a chief executive officer from October 2000 through July 2008 and previously chief financial officer and president and chief operating officer. Mr. Mott led the sale of MedImmune to AstraZeneca in June 2007 for $15.6 billion. Earlier in his career, he was a vice president in healthcare investment banking at Smith Barney, Harris Upham & Co., Inc. Across his career, as chairman, chief executive officer, board member, general partner, or operating executive, Mr. Mott has been involved in over $40 billion in corporate acquisitions, fundraising, partnerships, and other capital formation. He has been involved in more than 35 initial public offerings or corporate acquisitions, in bringing over a dozen new drugs through development to commercialization, and has served on 25 corporate boards. Mr. Mott is currently Chairman of several public biotechnology companies: Adaptimmune (ADAP), Ardelyx (ARDX), Epizyme (EPZM), Imara (IMRX), Mersana (MRSN), and serves on the board of directors of Novavax (NVAX). Mr. Mott earned a B.A. from Dartmouth College.